View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. News
March 30, 2022

SDP Oncology doses first subject in Phase I/II leukaemia therapy trial

The open-label trial will have dose-escalation and dose-expansion portions to analyse DSP-5336 in AML or ALL patients.

Sumitomo Dainippon Pharma Oncology (SDP Oncology) has dosed the first subject in the Phase I/II clinical trial of its therapy DSP-5336 in relapsed or refractory (r/r) acute myeloid leukaemia (AML) or acute lymphocytic leukaemia (ALL) patients.

DSP-5336 is a small molecule inhibitor of menin binding to mixed-lineage leukaemia (MLL) protein.

The open-label trial will have dose-escalation and dose-expansion parts.

Evaluating DSP-5336’s safety and tolerability in r/r AML or ALL patients and selecting the recommended Phase II dose (RP2D) are the primary objectives of the Phase I dose-escalation segment of the trial.

Analysing the initial clinical activity of DSP-5336 in adult patients will be included as a secondary objective.

On concluding the Phase I portion, the trial will advance into the Phase II dose expansion portion of the study.

To further assess the safety and clinical activity of DSP-5336 in adult r/r AML patients with MLL rearrangement or nucleophosmin 1 (NPM1) mutation is the primary objective of this portion of the trial.

Sumitomo Dainippon Pharma Oncology CEO, Oncology global head Patricia Andrews said: “Patients with refractory or relapsed AML or ALL have an unfavourable prognosis and respond poorly to available treatments.

“Dosing the first patient in our Phase I/II study is an important milestone as we evaluate DSP-5336 and its safety and potential benefits for this patient population.

“It is our hope that the data generated by this study furthers our goal of advancing meaningful treatments for patients with blood cancer.”

According to preclinical data, disruption of fusion and wild-type menin-MLL interactions hinders leukemic cell multiplication and reinstates terminal differentiation of MLL-rearranged and NPM1–mutated leukemic cells.

DSP-5336 is said to attach to menin to MLL fusion and wildtype proteins leading to the upregulation of HOXA family and MEIS1 genes that act in stopping myeloid cellular differentiation and elicit leukemogenic transformation.

Related Companies

Free Whitepaper
img

Unlocking the clinical trial potential of Africa

Ongoing improvements around infrastructure, continued investment, and being home to one of the world’s largest working age populations, means that Africa’s role in the clinical trials market has transformed. In this whitepaper, Oximio outlines the dynamics of today’s clinical trial market in Africa, including the key challenges the region is facing and how sponsors can overcome them to unlock the continent’s growing potential.
by Oximio
Enter your details here to receive your free Whitepaper.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU